Andere Sprachen CureVac N.V. Deutsche Boerse AG

Aktien

A2P71U

NL0015436031

5CV

Markt geschlossen - Deutsche Boerse AG Andere Börsenplätze 20:23:17 10.06.2024			% 5 Tage	% 1. Jan.
4.2 ^EUR	+1.06%		+17.32%	+9.38%

04.06.	Öl- und Bankentitel schwach - EZB wirft Schatten voraus	DJ
04.06.	XETRA-SCHLUSS/DAX schwächer - der Bund macht Kasse	DJ

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza, Development in Collaboration with GSK	29.05.
CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate	28.05.
CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK	28.05.
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK	28.05.
CureVac N : Proxycard AGM 2024	24.05.
CureVac N : Dutch Statutory Board Report and Financial Statements of CureVac N.V. 2023	24.05.
CureVac N : Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) - Form 6-K	23.05.
CureVac N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	23.05.
CUREVAC : Significant cash drain in the Q1	23.05.
CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update	23.05.
Health Care Up as Vaccine Makers Gain - Health Care Roundup	22.05.
CUREVAC : A missed opportunity	02.05.
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza Development in Collaboration with GSK	25.04.
CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	25.04.
CureVac Begins Early Stage Portion of Investigational Vaccine Trial	24.04.
CureVac Hires New Chief Business Officer	24.04.
CureVac, GSK Launch Phase 1/2 Trial of Bird Flu Vaccine Candidate	24.04.
Earnings Flash (CVAC) CUREVAC Posts Q4 Revenue EUR22.6M	24.04.
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024	24.04.
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza; Development in Collaboration with GSK	24.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

CUREVAC : Erheblicher Bargeldabfluss im Q1

Am 23. Mai 2024 um 21:49 Uhr